Adding TIGIT Targeting Tops PD-1 Alone in Mid-Stage NSCLC Trial

(MedPage Today) -- Use of a PD-1/TIGIT inhibitor combination in patients with metastatic non-small cell lung cancer (NSCLC) and high PD-L1 expression resulted in improved response rates and progression-free survival (PFS) compared with PD-1 inhibition...